Caseware UK (AP4) 2024.0.164 2024.0.164 2024-08-312024-08-312023-09-01falseNo description of principal activity22truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 12507033 2023-09-01 2024-08-31 12507033 2022-09-01 2023-08-31 12507033 2024-08-31 12507033 2023-08-31 12507033 c:Director1 2023-09-01 2024-08-31 12507033 c:Director2 2023-09-01 2024-08-31 12507033 c:RegisteredOffice 2023-09-01 2024-08-31 12507033 d:OfficeEquipment 2023-09-01 2024-08-31 12507033 d:OfficeEquipment 2024-08-31 12507033 d:OfficeEquipment 2023-08-31 12507033 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-09-01 2024-08-31 12507033 d:CurrentFinancialInstruments 2024-08-31 12507033 d:CurrentFinancialInstruments 2023-08-31 12507033 d:CurrentFinancialInstruments d:WithinOneYear 2024-08-31 12507033 d:CurrentFinancialInstruments d:WithinOneYear 2023-08-31 12507033 d:ShareCapital 2024-08-31 12507033 d:ShareCapital 2023-08-31 12507033 d:RetainedEarningsAccumulatedLosses 2024-08-31 12507033 d:RetainedEarningsAccumulatedLosses 2023-08-31 12507033 c:OrdinaryShareClass1 2023-09-01 2024-08-31 12507033 c:OrdinaryShareClass1 2024-08-31 12507033 c:OrdinaryShareClass2 2023-09-01 2024-08-31 12507033 c:OrdinaryShareClass2 2024-08-31 12507033 c:OrdinaryShareClass3 2023-09-01 2024-08-31 12507033 c:OrdinaryShareClass3 2024-08-31 12507033 c:FRS102 2023-09-01 2024-08-31 12507033 c:AuditExemptWithAccountantsReport 2023-09-01 2024-08-31 12507033 c:FullAccounts 2023-09-01 2024-08-31 12507033 c:PrivateLimitedCompanyLtd 2023-09-01 2024-08-31 12507033 d:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2023-09-01 2024-08-31 12507033 d:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-08-31 12507033 d:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2023-08-31 12507033 e:PoundSterling 2023-09-01 2024-08-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 12507033









TRANSLATIONAL DIAGNOSTICS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 AUGUST 2024

 
TRANSLATIONAL DIAGNOSTICS LIMITED
 
 
COMPANY INFORMATION


Directors
Dr T D Turmezei 
Dr V K Wong 




Registered number
12507033



Registered office
7 The Close

Norwich

Norfolk

NR1 4DJ




Accountants
MA Partners LLP
Chartered Accountants

7 The Close

Norwich

Norfolk

NR1 4DJ





 
TRANSLATIONAL DIAGNOSTICS LIMITED
 

CONTENTS



Page
Accountants' report
 
 
1
Balance sheet
 
 
2 - 3
Notes to the financial statements
 
 
4 - 7


 
TRANSLATIONAL DIAGNOSTICS LIMITED
 
 
  
CHARTERED ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF TRANSLATIONAL DIAGNOSTICS LIMITED
FOR THE YEAR ENDED 31 AUGUST 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Translational Diagnostics Limited for the year ended 31 August 2024 which comprise  the Balance sheet and the related notes from the Company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW)we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com /regulation.

This report is made solely to the Board of directors of Translational Diagnostics Limited, as a body, in accordance with the terms of our engagement letter dated 14 December 2023Our work has been undertaken solely to prepare for your approval the financial statements of Translational Diagnostics Limited and state those matters that we have agreed to state to the Board of directors of Translational Diagnostics Limited, as a body, in this report in accordance with ICAEW Technical Release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Translational Diagnostics Limited and its Board of directors, as a body, for our work or for this report. 

It is your duty to ensure that Translational Diagnostics Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Translational Diagnostics Limited. You consider that Translational Diagnostics Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or review of the financial statements of Translational Diagnostics Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

  





MA Partners LLP
 
Chartered Accountants
  
7 The Close
Norwich
Norfolk
NR1 4DJ

5 March 2025
Page 1

 
TRANSLATIONAL DIAGNOSTICS LIMITED
REGISTERED NUMBER: 12507033

BALANCE SHEET
AS AT 31 AUGUST 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
1,277
1,222

  
1,277
1,222

Current assets
  

Debtors: amounts falling due within one year
 5 
25,601
35

Cash at bank and in hand
  
26,070
4,577

  
51,671
4,612

Creditors: amounts falling due within one year
 6 
(12,241)
(3,098)

Net current assets
  
 
 
39,430
 
 
1,514

Total assets less current liabilities
  
40,707
2,736

Provisions for liabilities
  

Deferred tax
  
(319)
(232)

  
 
 
(319)
 
 
(232)

Net assets
  
40,388
2,504


Capital and reserves
  

Called up share capital 
 7 
90
90

Profit and loss account
  
40,298
2,414

  
40,388
2,504


Page 2

 
TRANSLATIONAL DIAGNOSTICS LIMITED
REGISTERED NUMBER: 12507033
    
BALANCE SHEET (CONTINUED)
AS AT 31 AUGUST 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 5 March 2025.






Dr T D Turmezei
Director

The notes on pages 4 to 7 form part of these financial statements.

Page 3

 
TRANSLATIONAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024

1.


General information

The Company is a private company limited by shares. It is both incorporated and domiciled in England and Wales. The address of its registered office is 7 The Close, Norwich, Norfolk, NR1 4DJ.
The Company's principal activity is that of medical consultancy and the Company's principal place of activity is East Anglia.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Turnover comprises revenue recognised by the company in respect of medical consultancy services supplied during the year.

 
2.3

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.
Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

 
2.4

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
TRANSLATIONAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024

2.Accounting policies (continued)


2.4
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment
-
3 years straight-line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.5

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.8

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors.
Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured at the undiscounted amount of the cash or other consideration expected to be paid or received.

 
2.9

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

Page 5

 
TRANSLATIONAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024

3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2023 - 2).


4.


Tangible fixed assets





Office equipment

£



Cost or valuation


At 1 September 2023
1,833


Additions
999



At 31 August 2024

2,832



Depreciation


At 1 September 2023
611


Charge for the year on owned assets
944



At 31 August 2024

1,555



Net book value



At 31 August 2024
1,277



At 31 August 2023
1,222


5.


Debtors

2024
2023
£
£


Trade debtors
17,289
-

Prepayments and accrued income
8,312
35

25,601
35


Page 6

 
TRANSLATIONAL DIAGNOSTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024

6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Corporation tax
9,278
1,467

Other creditors
1,618
478

Accruals and deferred income
1,345
1,153

12,241
3,098



7.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



30 A Ordinary shares of £1.00 each
30
30
30 B Ordinary shares of £1.00 each
30
30
30 C Ordinary shares of £1.00 each
30
30

90

90



8.


Related party transactions

As at 31 August 2024, the balance due to the directors' from the Company was £1,618 (2023: £478).

 
Page 7